Nasdaq Markets

Image source: Getty Images

Americans are really worried about their retirement prospects. In fact, according to a recent SimplyWise survey, 62% of Americans are more concerned about retirement than they were a year ago. Retirement-related worries cover many different aspects of life after paychecks end,

When a large company is successful, one reason often cited is "economies of scale." The benefit of being big is that costs are spread across, or "scale" to cover, more and more situations. A doctor needs the same number of IT systems, buildings, and equipment to see 1,000 patien

When it comes to saving money for my kids to go to college, I use a 529 savings plan like many parents do. I also have some money set aside in a Uniform Gift to Minors Account (UGMA) for each of my children. Unlike with a 529, the UGMA money doesn't have to be used for college a

Dividends are back in the spotlight now that money market funds are yielding practically the same as the money you're stashing under your mattress. Even growth investors are starting to warm up to some income-producing stocks, but what about some of the names that have fallen si

If you know of Ryan Reynolds, you probably know him best for playing the potty-mouthed Marvel superhero in Deadpool -- or the more PG-rated Detective Pikachu. But did you know that Ryan Reynolds is also one heck of an investor?

Image source: Getty Images

After several months of steadily climbing upwards, the stock market has taken a downturn lately. This recent pullback might provide buying opportunities for stocks that are in a good position to succeed both during and after the coronavirus pandemic. The two companies that I'm k

AstraZeneca (NYSE: AZN) marked the first upset in the coronavirus vaccine race when it temporarily halted its clinical trials this week. The reason? One case of unexplained illness in a U.K. phase 3 trial participant. An independent panel will examine safety data concerning the

Long-term care is a huge financial burden faced by millions of seniors. In fact, there's a 70% chance that today's 65 year olds will need long-term care services sometime in the remainder of their lifetime -- and 1 in 5 will need them for more than five years. 

This has been a year that the investment community will remember for a long time. Aside from dealing with the unprecedented coronavirus disease 2019 (COVID-19) pandemic, Wall Street and investors have contended with the steepest bear market plunge of all time and the quickest ra

When stock market volatility drives me nuts, I find solace in dividend stocks. Or rather, I take comfort in top dividend stocks that I know will pay me a decent amount no matter what the market does. And there's nothing like bagging some of these top-class dividend-paying stocks

If there's a single word that could describe not just the stock market in 2020, but 2020 in general, it's "volatile." In March, stocks plunged when news of the COVID-19 pandemic broke, and while they subsequently staged a comeback, September has already gotten off to a rocky sta

At the beginning of 2020, Altimmune (NASDAQ: ALT) and Vaxart (NASDAQ: VXRT) were tiny biotechs with market caps below $30 million. They weren't even big enough to be considered microcap stocks. Most investors had never heard of either company.

For more than 80 years, Social Security has been providing a financial foundation for retired workers. Data from the Social Security Administration finds that 62% of all current retirees rely on the program for at least half of their monthly income, with 34% leaning on Social Se

(RTTNews) - Shares of 10x Genomics Inc. (TXG), which closed at an all-time high of $125 on Friday, have gained 64 percent so far this year.

One of the top dividend stocks in the healthcare sector is getting ready to hand out some cash to shareholders yet again. AbbVie (NYSE: ABBV) announced Friday that its board of directors has declared a fresh quarterly dividend of $1.18 per share.

The markets might be in turmoil, but spare a thought for the current woes at biotech Amarin (AMRN). Over the past 7 trading sessions, shares have retreated by 44% as investors charged to the exit doors following a botched date in court.

Last week, an appeals court rejected Amarin’s appeal concerning a lost patent court case against generic drug makers Hikma Pharmaceuticals and Dr. Reddy’s, who are seeking to bring to market their own versions of Amarin’s high triglyceride treatment Vascepa.

As Vascepa is Amarin’s only product, the ruling has obviously spooked investors, who are concerned the treatment’s vast commercial opportunity is fading fast. However, Cantor analyst Louise Chen argues the game is far from over.

Chen said, “We continue to think that AMRN's EU opportunity is underappreciated and that generics companies will not be able to manufacture enough product to meet the demand in the U.S. market. We still believe that AMRN may generate strategic interest, possibly from an EU company with an established cardiovascular franchise.”

Chen’s remarks echo those made by Amarin following the negative ruling. The company will request an en banc review of the panel decision, but in the meantime have stressed its “go-forward strategy” remains the same. Regulatory approval for Vascepa in the EU is expected shortly and Amarin should launch Vascepa in the region early next year.

Furthermore, the biotech and its partners are still in the hunt for additional regulatory approvals for Vascepa in China, and in additional countries in the Middle East (Vascepa is already approved in Lebanon and the United Arab Emirates), and “remain confident in the global market potential of Vascepa.”

All in all, Chen rates AMRN an Overweight (i.e. Buy), although the “downward earnings estimate revisions for U.S. sales of Vascepa” result in a price target reduction. The figure is slashed from $35 to $15. Nevertheless, upside from current levels is a plentiful 268%. (To watch Chen’s track record, click here)

The rest of the Street also expects more upside. Going by the $11.38 average price target, the analysts expect shares to add a hefty 179% over the next 12 months. The stock currently has a Moderate Buy consensus rating, based on 6 Buys and 4 Holds. (See AMRN stock analysis on TipRanks)

To find good ideas for stocks trading at attractive valuations, visit TipRanks’ Best Stocks to Buy, a newly launched tool that unites all of TipRanks’ equity insights.

Disclaimer: The opinions expressed in this article are solely those of the featured analysts. The content is intended to be used for informational purposes only. It is very important to do your own analysis before making any investment.